# Habico A/S

Energivej 15 5260 Odense S

Central Business Registration no. 75 12 85 17

# Annual report 2017

The Annual General Meeting adopted the annual report on \_\_\_\_/ 2018

Chairman of the General Meeting:

Kim Jensen



# Table of contents

	Page
Company details	3
Statement by management	4
Independent auditor's report	5
Group structure	8
Management's commentary	9
Income statement for 2017	17
Balance sheet at 31.12.2017	18
Statement of changes in equity for 2017	20
Cash flow statement for 2017	21
Notes	22
Accounting policies	28

# **Company details**

# Company

Habico A/S Energivej 15 5260 Odense S Central Business Registration No: 75 12 85 17 Registered in: Odense

# **Board of Directors**

Ole Michael Friis, Chairman Birgitte Bøgh-Sørensen Hans Carl Bøgh-Sørensen

# Group executive board

Hans Carl Bøgh-Sørensen, Chief Executive Officer

# **Company auditors**

Deloitte Statsautoriseret Revisionspartnerselskab

# Statement by Management on the annual report

The Board of Directors and the Executive Board have today considered and approved the annual report of Habico A/S for the financial year 01.01.2017 - 31.12.2017.

The annual report is presented in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the Entity's financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017. We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.

We recommend the annual report for adoption at the Annual General Meeting.

Odense, 2. Juni 2018

**Executive Board** 

Hans Carl Bøgh-Sørensen Chief Executive Officer

**Board of Directors** 

Ole Michael Friis Chairman Birgitte Bøgh-Sørensen

Hans Carl Bøgh-Sørensen

# Independent auditor's report To the shareholders of Habico A/S

# Opinion

We have audited the consolidated financial statements and the parent financial statements of Habico A/S for the financial year 01.01.2017 - 31.12.2017, which comprise the income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies, for the Group as well as the Parent, and the consolidated cash flow statement. The consolidated financial statements and the parent financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the consolidated financial statements and the parent financial statements give a true and fair view of the Group's and the Parent's financial position at 31.12.2017, and of the results of their operations and the consolidated cash flows for the financial year 01.01.2017 - 31.12.2017 in accordance with the Danish Financial Statements Act.

# **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the *Auditor's responsibilities for the audit of the consolidated financial statements and the parent financial statements* section of this auditor's report. We are independent of the Group in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

# Management's responsibilities for the consolidated financial statements and the parent financial statements

Management is responsible for the preparation of consolidated financial statements and parent financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of consolidated financial statements and parent financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements and the parent financial statements, Management is responsible for assessing the Group's and the Parent's ability to continue as a going concern, for disclosing, as applicable, matters related to going concern, and for using the going concern basis of accounting in preparing the consolidated financial statements and the parent financial statements unless Management either intends to liquidate the Group or the Entity or to cease operations, or has no realistic alternative but to do so.

# Auditor's responsibilities for the audit of the consolidated financial statements and the parent financial statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements and the parent financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements and parent financial statements. As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

• Identify and assess the risks of material misstatement of the consolidated financial statements and the parent financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

• Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's and the Parent's internal control.

• Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.

• Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the consolidated financial statements and the parent financial statements, and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's and the Parent's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements and the parent financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and the Entity to cease to continue as a going concern.

• Evaluate the overall presentation, structure and content of the consolidated financial statements and the parent financial statements, including the disclosures in the notes, and whether the consolidated financial statements and the parent financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

• Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

#### Statement on the management commentary

Management is responsible for the management commentary.

Our opinion on the consolidated financial statements and the parent financial statements does not cover the management commentary, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements and the parent financial statements, our responsibility is to read the management commentary and, in doing so, consider whether the management commentary is materially inconsistent with the consolidated financial statements and the parent financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the management commentary provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that the management commentary is in accordance with the consolidated financial statements and the parent financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of the management commentary.

Odense, 2. Juni 2018


# Deloitte

Statsautoriseret Revisionspartnerselskab Business Registration No 33 96 35 56

Allan Dydensborg Madsen
State-Authorised
Public Accountant
MNE Number mne34144



100%



8

# Financial highlights of the Group

(mio. EUR) Key figures	2017	2016	2015	2014	2013
Revenue	796,9	725,8	759,1	755,0	727,2
Gross profit	120,4	108,7	96,9	91,2	95,6
Operating income	33,8	24,4	20,0	16,2	16,0
Net financials	-3,0	-6,1	-4,5	-3,1	-2,8
Profit for the year	23,5	11,7	12,4	9,3	10,2
Investments in Tangible fixed assets	4,1	3,0	2,8	1,4	2,2
Inventories	151,4	148,6	119,2	143,0	142,6
Receivables from sales	111,7	95,4	95,0	78,3	81,8
Equity	135,7	115,6	105,8	96,1	89,1
Total assets	370,0	350,2	325,5	289,7	303,2
Ratios					
Gross margin (%)	15,1	15,0	12,8	12,1	13,1
Operating margin (%)	4,2	3,4	2,6	2,1	2,2
Equity ratio (%)	36,7	33,0	32,5	33,2	29,4
Return on equity (%)	18,7	10,6	12,3	10,0	12,1

In 2017, Habico reached a strong level of earnings with 2017 financial being the 2<sup>nd</sup> strongest financial year ever in company history. Especially the business unit Orifarm Parallel Import showed an excellent development and result through new market entries and growth on mature markets and thereby increasing the society savings on pharmaceuticals. Orifarm Generics invested further in order to create long-term growth.

- Habico's revenues increased by 9.8% to MEUR 797 (2016: MEUR 726). Operating income excl. non-recurring items increased by MEUR 1.6 to MEUR 33.8 (2016: MEUR 32.2) and earnings before tax increased by MEUR 12.3 to MEUR 28.7 (2016: MEUR 16.4)
- Orifarm Parallel Import's revenues totalled MEUR 720 (2016: MEUR 646). Operating income excl. non-recurring items increased by MEUR 4.2 to MEUR 26.2 (2016: MEUR 22.0)
- Orifarm Generics' revenues fell slightly to MEUR 77 (2016: MEUR 79). Operating income fell by MEUR 2.0 to MEUR 12.3 (2016: MEUR 14.3)

# **Company Presentation**

Habico is an ambitious operator in the European market for pharmaceuticals. Our ambition is to supply high quality pharmaceuticals at a lower cost. In other words: We offer consumers and societies more healthcare for their money.

Habico consists of two operating divisions: Orifarm Parallel Import and Orifarm Generics.

Common to both operating divisions is healthcare business model innovation. This is expressed in Habico's mission statement which is "*Challenging the pharmaceutical market*".

Habico's vision - "We want to be number 1 in making healthcare a better deal" - expresses the general objective. "A better deal" refers not only to savings, but also to how Habico delivers solutions that meet its stakeholder's needs. Habico's operating activities are guided by our values which are flexibility, ambition, responsibility and customer focus.

# **Orifarm Parallel Import**

Orifarm Parallel Import was established in 1994 in response to significant price differentials for identical pharmaceuticals across EU Member States. Pharmaceuticals are imported from EU/EEA Member States where original pharmaceutical producers sell their preparations at prices that are lower than what they demand for the identical products in e.g. the Nordic countries and Germany. In doing so, Habico utilises the principle of free movement of goods within the EU/EEA.

Orifarm Parallel Import's activities have led to lower prices of pharmaceuticals and thus savings benefitting both patients and society at large in the markets in which it operates.

Despite the principles of free movement of goods within the EU/EEA, and without regard for the fact that the efforts of Orifarm Parallel Import and its competitors have led to lower costs of pharmaceuticals, various barriers to the parallel import trade are still being tolerated by the EU; see section entitled "Obstacles to healthcare cost savings generated by the Parallel Import trade" below.

# **Orifarm Generics**

Habico entered the generic pharmaceuticals market in the Nordic countries in 2001. Generic pharmaceuticals can be produced and marketed once the original manufacturer's patent expires and its exclusive rights lapse. Generic competition normally lowers prices on medicine significantly which benefits patients and society at large.

Included in Orifarm Generics' broad range of generic preparations is a line of generic over-thecounter products which are marketed under the umbrella brand "Tænk gult" in Denmark and "Tänk Gult" in Sweden.

# **Review of Financial Performance in 2017**

Habico's results for 2017 are considered satisfactory and in line with the expectations.

Habico's revenues increased by 9.8% to MEUR 797 (2016: MEUR 726) through dedicated focus on new market entries and organic growth in mature markets in Parallel Import.

Habico's gross margin increased by 0.1%-points to 15.1% (2016: 15.0%) due to slightly lower proportionate share of turnover in the low margin business of Parallel Import.

Habico's operating margin increased to 4.2% (2016: 3.4%) through dedicated focus on profitability in Parallel Import. Habico's operating income increased by MEUR 9.3m to MEUR 33.8 (2016: MEUR 24.5).

# 2017 Performance Highlights – Orifarm Parallel Import

- Although market conditions were challenging, PI achieved margin improvements and an overall significant improvement in net result
- Orifarm Parallel Import's revenues totalled MEUR 720 (2016: MEUR 646)
- Orifarm Parallel Import's operating income excl. non-recurring items totalled MEUR 26.2 (2016: MEUR 22.0)
- Orifarm Parallel Import maintained its leading position as Europe's largest parallel importer of pharmaceuticals
- In Germany, operating profit were lifted through dedicated efforts and despite fierce price competition
- In Sweden, operating income as well as margins were under significant pressure due to the weak Swedish Krona. Orifarm's market leading position was maintained
- In Denmark, profitability was increased despite fierce competition
- Orifarm entered the UK market under full awareness of potential consequences from BREXIT. The weakened British Pound, however, has led to pressure on profitability, but as UK is the second largest PI market in Europe, Orifarm continues to see mid-term possibilities

- Activity level and profitability from presence on the Dutch market increased significantly in 2017 despite challenging entry barriers
- Orifarm gained significant market shares on the Austrian market

# 2017 Performance Highlights – Orifarm Generics

- Orifarm Generics' revenues fell slightly to MEUR 77 (2016: MEUR 79)
- Operating income fell by MEUR 2.0 to MEUR 12.3 (2016: MEUR 14.3) due to significant investments in mid-long term growth
- Orifarm Generics had a strong 1<sup>st</sup> half with growth across segments but encountered fierce price competition in 2<sup>nd</sup> half (especially Denmark and Sweden). In summary, this ended in a stagnant turnover for the year
- Own-developed niche products for the Rx segment (prescribed medicine) continued a satisfactory development along side with a strong general assortment-wide growth within the Rx segment
- Orifarm Generics maintained its strong position across the Denmark and Sweden markets within the segment for over-the-counter pharmaceuticals
- Orifarm Generics decided to invest further in developing new products in order to achieve long-term growth and thereby additional society savings

# Obstacles to Healthcare Cost Savings Generated by the Parallel Import trade

A series of measures undertaken by original producers and by some EU Member States hamper trade in pharmaceuticals and reduce Habico's ability to grow its parallel-import business:

# Quota systems

A number of the world's biggest pharmaceutical manufacturers have introduced quota systems for selling pharmaceuticals in the EU. In some cases, pharmaceutical manufacturers have gone even further and stopped making deliveries to wholesalers who are re-exporting pharmaceuticals. This practise limits Habico's sourcing opportunities and consequently also the capacity to increase sales of the lower priced parallel imported pharmaceuticals. In Habico's view, quota systems are in breach of the EU Treaty because they let pharmaceutical manufacturers restrict competition within the EU.

# Export ban

Several EU Member States have introduced or attempted to introduce bans on exports of pharmaceuticals to other member states or have hampered exports by imposing obligations onto exporters' notification as regards to regulatory authorities and approval regimens prior to export. Export bans and disproportionate export barriers violate the EU Treaty's provisions on the free movement of goods and may change Habico's entire business model. We therefore strongly object to such measures. The European Commission is regularly informed about developments and in this context we are pleased to note that the Commission is currently investigating the extent of such export restrictions with the purpose of potential political intervention.

# Dual pricing

In Spain, a number of multinational pharmaceutical manufacturers have established or maintained – supported by a legal frame work initiated by the Government – a dual pricing system. Dual pricing forces pharmaceutical manufacturers to sell their products at an artificially inflated price to Spanish pharmaceutical wholesalers. However, if the wholesalers can document that the products are intended for domestic sale - and not for re-export – then wholesalers will receive a discount bringing the price to the 'normal' Spanish price level. For parallel importers, the dual-pricing system, therefore, means that one of the EU's fundamental principles - free movement of goods between union members states - is effectively overruled. In Habico's opinion, dual-priding violates the competition provisions set out in the EU Treaty.

Nonetheless, despite these trade restrictions, Habico has continued to provide its customers with stable deliveries of goods by cultivating new procurement countries and channels.

# **Special Risks**

# Operating conditions

To a significant extent, consolidated earnings depend on legislative measures that affect the pricing of pharmaceuticals in both the purchase and the sales countries. Earnings are also affected by measures in the sales countries which are intended to limit the consumption of pharmaceuticals.

It is Habico's policy to avoid infringing on trademark rights, and Habico is not currently involved in any major pending litigation of this kind.

For the business area Generic Pharmaceuticals, Habico policy states that infringing on patent rights should be avoided. However, since patent holders have a significant commercial interest in defending market monopolies that exceed the protections granted by a given patent, and since manufactures of generic products have an interest in challenging the market at patent expiry, disputes and litigation are difficult to avoid. Habico is from time to time involved in pending legal proceedings. The outcome of these may affect Habico's earnings.

# Financial matters

Habico is exposed to fluctuations in foreign exchange rates and interest rate levels. The risks are mitigated through hedge, in accordance with the Group's policy. Exchange rate risks are primarily related to the currencies SEK, CZK and GBP. A 1 percentage point change in the interest rate level affects the Group's earnings net by approx. MEUR 1.0.

Habico's financial risks, including its cash management and extension of credits, are managed centrally. The aim is to maintain a low risk profile.

# **Culture and Employees**

It is Habico's objective to be a leading supplier of parallel-imported and generic pharmaceuticals in the Nordic countries, Germany, Austria, Holland and UK. We believe that our results and the competencies and commitment of our employees are intertwined. That is why we are constantly seeking to develop our employees' knowledge and competencies, which in turn bolster Habico's results and growth-oriented culture.

Habico is aware of its social responsibilities and accordingly, it is important for the company to have a wide variety of employees. Consequently, the company is stressing internal efforts to integrate employees of other ethnic backgrounds as well as disabled employees.

The level of internationalisation in Habico has increased significantly in recent years, and Habico has conducted international rotations of employees to ensure integration, knowledge sharing and cultural exchange.

# **Target Figures for Gender Composition of Management**

At Habico, diversity is considered a strength that opens up access to the most talented employees.

Offering excellent career opportunities to both female and male employees helps to ensure that Habico has the capacity of appointing the best candidate for a given position. This is also reflected in the gender distribution among our executives in Danish companies where 40% are female and 60% are male.

The policy is to recruit the best candidate for a given position. If more candidates are assessed equal on competencies, the underrepresented gender will be chosen for the position. The ambition is to have at least 40% of both sexes represented on Habico's management team.

The Supervisory Board of Habico A/S currently consists of 3 general elected members of whom 1 is woman.

# **Corporate Social Responsibility**

During 2017 the Management of Habico took initiative to update its CSR policies. The new and enhanced policies were approved by the Board of Directors in December 2017. Accordingly monitoring of the effects have been initiated in 2018, and the results will be published as part of the Annual Report for 2019.

The Orifarm CSR efforts and execution ensure compliance with the Danish Financial Statement Act § 99 a and b. We have identified areas in which we have the possibility to positively impact a sustainable development or are at risk of impacting human rights, labour rights, climate and environment in a negative way or being complicit to corruption and bribery.

Our CSR efforts are aligned with the UN Global Compact Principles, and we strive at pursuing the goals and standards mentioned in the UN Guiding Principles for Human Rights and Business and the OECD guidelines for multinational enterprises.

# **Climate and Environment**

It is our aim to contribute to a better environment by ensuring that environmental concerns form a natural part of all our activities. This includes a precautionary approach to environmental challenges and promotion of environmentally friendly technologies internally in the Group and among business partners.

Habico affects the environment primarily through the consumption of energy and resources in our buildings and for transportation, but also via our production. We therefore constantly work to reduce our energy consumption and emissions and improve waste management. We apply a systematic approach to environmental management and comply with all legislative requirements.

To minimize environmental impact, we have incorporated an environmental policy throughout the whole organization that guides us on how to take care of the environment in daily life.

Actions initiated in 2016 have been continued and further strengthened during 2017 for the benefits of a better environment and a more profitable business.

Further investments in new and improved facilities and technical installations have been completed in the Group. Energy efficiency and savings have been highly considered as part of these investments.

These actions have led to a reduction of Co2 emission even though we have not yet implemented measurements.

Planned new environmental initiatives for 2018 cover a switch to sustainable energy solutions ("green energy"), replacement of freon based refrigeration plants and conversion of food waste to biofuel.

# Human Rights

In all Habico operations and activities we respect human rights and avoid infringing the human rights of involved individuals.

We believe that through our products we may contribute in a positive manner to the human rights to health and wellbeing by paving the way for accessibility to affordable and high-quality medicine for all.

To reduce the risk for setting aside relevant human rights for our business, we ensure compliance with human rights related legislation and identify actual and potential risks from activities in our business units and facilities. Identified risks that are directly linked to our operations and to the services of our business partners are mitigated and prevented.

In Europe we thus have a focus on privacy and protection of personal data throughout the Group, covering both the data of consumers, employees and business partners.

# Labour Rights

It is important to us that sustainable management is visible in all parts of our organization. To achieve this, we have a strong and continuous focus on taking good care of our employees and to create a motivating environment where our employees thrive and develop.

We value being a social and friendly organization that accommodates diversity. Diversity in Habico is about recognizing employees because of, not despite of the fact that they are different. We see the potential of each employee and create opportunities for everyone to develop at work, irrespective of their gender, ethnicity, disability or other personal characteristics. Diversity thus provide us with an opportunity to share experiences and gather learnings across different cultures and to transform this knowledge into a competitive advantage.

The well-being and motivation of our employees are dependent on a healthy and safe workplace. To ensure this, we comply with legislation and collective agreements on fair wages, rest and leisure, equal remuneration for men and women, anti-discrimination and equal opportunities in access to employment and career.

In our supply chain and with other business partners we are committed to identify and mitigate or eliminate any risk for infringing the right to freedom of association and to collective bargaining. We are also committed to eliminate all forms of forced and compulsory labour and to effectively abolish child labour.

# Anti-corruption and Bribery

Habico places great emphasis on being a good and competent partner for our stakeholders. Part of this involves working against corruption and to promote good business ethics.

Our anti-corruption effort includes prevention of extortion and bribery and is carried out in compliance with international standards. In our Supplier Code of Conduct our suppliers and business partners are requested to support and respect anti-corruption principles. At the same time we conduct risk assessments and mitigations plans as an integrated part of our business planning and operations.

# **Development Activities**

Habico's two business areas both have significant development activities covering both product and process development.

# Events since the End of the Fiscal Year

From the reporting date until today, no events have occurred which could change the assessments made in the Annual Report.

# Outlook

Habico expects activity and results for 2018 to be at same level as 2017.

# Income statement

Parent co	ompany			Grou	р
2016	2017		Note_	2017	2016
		Revenue	1	796.905	725.777
		Other operating income		1.538	404
		Cost of sales		-678.085	-617.524
		Gross profit		120.358	108.657
-117	-46	Other external expenses		-32.001	-32.318
		Staff costs	2 _	-45.241	-42.980
-117	-46	Income before depreciation		43.116	33.359
0	0	Depreciation, amort. and impairm. losses	3 _	-9.313	-8.978
-117	-46	Operating income		33.803	24.381
10.181	21.881	Income from investments in group entities	4		
3.907	2.144	Financial income	5	3.464	3.580
-1.875	0	Financial expenses	6 _	-6.450	-9.687
12.096	23.979	Profit before tax		30.817	18.274
-429	-473	Тах	7	-7.311	-6.607
11.667	23.506	Profit for the year	8	23.506	11.667

# **Balance sheet**

	ompany			Grou	р
2016	2017		Note_	2017	2016
		Goodwill		46.909	48.526
		Files and application fees		19.403	19.712
		Other intangible assets		1.979	2.888
		Development projects in progress	_	719	0
		Intangible assets	9 _	69.010	71.126
		Property		18.588	19.829
		Leasehold improvements		82	65
		Plant and equipments	_	5.407	3.201
		Tangible fixed assets	10 _	24.077	23.095
98.486	117.046	Investments in group entities	11		
13.950	9.807	Receivables from group entities			
0	0	Other bonds and equity investments	12 _	645	28
112.436	126.853	Financial assets	_	645	28
112.436	126.853	Fixed assets	_	93.732	94.249
0	0	Inventories	13 _	151.405	148.576
		Receivables from sales		111.742	95.356
3.898	9.323	Receivables from group entities		9.624	3.810
					705
0	25	Other receivables		1.276	765
	25	Other receivables Prepayments	14	1.276 928	
	25		14 15		1.432
	25	Prepayments		928	765 1.432 2.236 720
		Prepayments Deferred tax assets		928 462	1.432 2.236 720
0		Prepayments Deferred tax assets Income taxes		928 462 747	1.432 2.236 720 <b>104.319</b>
0 3.898	9.348	Prepayments Deferred tax assets Income taxes Receivables Cash		928 462 747 <b>124.779</b>	1.432 2.236

# **Balance sheet**

Parent c	ompany			Grou	р
2016	2017		Note_	2017	2016
3.682	3.683	Share capital	16	3.683	3.682
64.536	83.096	Reserve for net revaluation of equity holdir	ngs		
43.971	42.214	Retained earnings	-	125.310	108.507
3.363	6.716	Proposed dividends for the year	_	6.716	3.363
115.552	135.709	Total equity	_	135.709	115.552
		Deferred tax liabilities	15 _	3.185	4.626
		Provisions	_	3.185	4.626
0	0	Mortgage debt		5.093	5.408
0	0	Bank loan		22.339	39.956
0	0	Long-term liabilities	17 _	27.432	45.364
		Short-term portion of long-term liabilities	17	18.588	10.868
35	30	Bank debt		94.732	96.847
0	0	Trade payables		52.962	43.099
423	462	Income taxes		6.442	5.461
324	0	Other debt	_	30.905	28.413
782	492	Short-term liabilities	_	203.629	184.688
782	492	Liabilities	_	231.061	230.052
116.334	136.201	Total equity, provisions and liabilities	_	369.955	350.230

Pledged assets and contingent liabilites	18
Other notes	19-25

# Statement of changes in equity (1.000 EUR)

	Group				
	Share capital	Retained earnings	Proposed dividend	Total	
Equity at 01.01.2017	3.682	108.507	3.363	115.552	
Exchange rate adjustments	1	-379	0	-378	
Adjustment of hedging instruments	0	392	0	392	
Distributed dividend	0	0	-3.363	-3.363	
Profit for the year	0	16.790	6.716	23.506	
Equity at 31.12.2017	3.683	125.310	6.716	135.709	

# Parent company

	Share capital	Net revaluation equity method	Retained earnings	Proposed dividend	Total
Equity at 01.01.2017	3.682	64.536	43.971	3.363	115.552
Exchange rate adjustments	1	-350	-29	0	-378
Adjustment of hedging instruments	0	392	0	0	392
Distributed dividend in the year	0	0	0	-3.363	-3.363
Profit for the year	0	18.518	-1.728	6.716	23.506
Equity at 31.12.2017	3.683	83.096	42.214	6.716	135.709

# Cash flow statement

		Group		
	Note	2017	2016	
Operating income		33.803	24.381	
Depreciation and impairment losses		9.313	8.978	
Exchange rate adjustments and hedging instruments on equity		50	67	
Change in other provisions		0	-5.164	
Working capital changes	19	-12.681	-30.466	
		30.485	-2.204	
Interests, net		-2.997	-6.107	
Income taxes paid		-6.127	-5.245	
Cash flows from operating activities		21.361	-13.556	
Acquisition of intangible assets, property, plant and equipment		-10.219	-9.012	
Sale of property, plant and equipment		2.119	6.468	
Change in deposits, fixed asset investments		-618	0	
Cash flows from investing activities		-8.718	-2.544	
Cash flows from operating and investing activities		12.643	-16.100	
Change in long-term liabilities other than provisions, net		-10.212	-13.081	
Dividend paid		-3.363	-2.015	
Cash flow from financing activities		-13.575	-15.096	
Increase/decrease in cash and cash equivalents		-932	-31.196	
Cash and equivalents 01.01.2017		-93.761	-62.565	
Cash and equivalents 31.12.2017	20	-94.693	-93.761	

Notes (1.000 EUR)

Parent c	ompany		Gro	up
2016	2017		2017	2016
		1. Segment information		
		Revenue		
		Parallelimport	717.627	646.498
		Generics	79.278	79.279
		Total	796.905	725.777
		2. Staff costs		
		Wages and salaries	35.934	34.807
		Pension costs	3.313	2.805
		Other social security costs	5.994	5.368
			45.241	42.980
		Of this, for Board of Directors	121	141
		Average number of employees	979	960
		Accumulated fees paid to executive board and		
		board of directors in the group, concerning		
		managerial work	1.239	1.040
		3. Depreciation, amort. and impairm. losses		
		Goodwill	1.557	1.557
		Files and applications	5.017	4.381
		Other intangible assets	1.131	1.651
		Buildings	577	495
		Operating equip. and leasehold improvements	1.031	894
			9.313	8.978
		4. Income from investments in group enterprises		
10.181	21.881	Share of profit/loss after tax		
10.181	21.881			
		5. Financial income		
3.904	2.144	Financial income, group enterprises	982	1.095
3	0	Other financial income	2.482	2.485
3.907	2.144		3.464	3.580

Notes (1.000 EUR)

Parent c	ompany		Group	
2016	2017		2017	2016
		6. Financial expenses		
0	0	Financial expenses, group enterprises	408	1.062
1.875	0	Other financial expenses	6.042	8.625
1.875	0		6.450	9.687
		7. Tax		
429	473	Current tax	6.710	5.317
0	0	Change in deffered tax	333	579
0	0	Adjustments concerning previous years	268	711
429	473		7.311	6.607

Group

# 8. Distribution of profit

6.716	Proposed dividend
18.518	Reserve for net revaluation of equity holdings
-1.728	Retained earnings
23.506	

9. Intangible assets	Goodwill	Files and application fees	Other intangible assets	Develop- ment projects in progress	Total
Cost at 01.01.2017	59.142	38.943	15.101	0	113.186
Additions	0	5.150	225	719	6.094
Exchange rate adjustments	-67	-389	-13	0	-469
Disposals	0	-893	-177	0	-1.070
Cost at 31.12.2017	59.075	42.811	15.136	719	117.741
Amortization 01.01.2017	10.616	19.231	12.213	0	42.060
Amortization for the year	1.557	5.017	1.131	0	7.705
Exchange rate adjustments	-7	-258	-10	0	-275
Reversal relating to disposals	0	-582	-177	0	-759
Amortization 31.12.2017	12.166	23.408	13.157	0	48.731
Carrying amount 31.12.2017	46.909	19.403	1.979	719	69.010
Carrying amount 31.12.2016	48.526	19.712	2.888	0	71.126

# Habico A/S

Group

# Notes (1.000 EUR)

10. Tangible fixed assets	Property	Leasehold improve- ments	Plant and equitment	Total
Cost at 01.01.2017	23.368	1.418	10.785	35.571
Additions	773	34	3.318	4.125
Exchange rate adjustments	244	-3	132	373
Disposals	-1.648	0	-696	-2.344
Cost at 31.12.2017	22.737	1.449	13.539	37.725
Depreciation 01.01.2016	3.539	1.353	7.584	12.476
Depreciation for the year	577	17	1.014	1.608
Exchange rate adjustments	33	-3	70	100
Reversal relating to disposals	0	0	-536	-536
Depreciation 31.12.2017	4.149	1.367	8.132	13.648
Carrying amount 31.12.2017	18.588	82	5.407	24.077
Carrying amount 31.12.2016	19.829	65	3.201	23.095

# Parent company

Cost at 01.01.2017	33.950
Cost at 31.12.2017	33.950
Net revaluation at 01.01.2017	64.536
Net share of profit/loss for the year	21.881
Dividend distributed during the year	-3.363
Adjustment of hedging on equity	392
Exchange rate adjustments	350_
Net revaluation 31.12.2017	83.096
Carrying amount 31.12.2017	117.046
Carrying amount 31.12.2016	98.486

Unamortised share of group goodwill on consolidation amounts 2.596 t.EUR.

Investments in group enterprises:	Country	Share
Orifarm Group A/S	Denmark	100%

See Group structure page 8

11. Investments in group entities

(1.000 EUR)

		Group	
		Deposits	Total
12. Other bonds an	d equity investments		
Cost at 01.01.2017		28	2
Additions		617	61
Cost at 31.12.2017		645	64
Carrying amount 31	.12.2017	645	64
Carrying amount 31.	12.2016	28	28
Parent company	<i>,</i>	Grou	qı
2016 2017		2017	2016
	13. Inventories		
	Raw materials and consumables	54.694	68.43
	Manufactured goods and goods for resale	96.711	80.138
		151.405	148.576
	14. Prepayments		
	Consists of prepayments on costs concerning subsequent financial y	ear.	
	15. Deferred tax		
	Deferred tax is incumbent on the following financial statement items:		
	Intangible assets	1.588	1.33

	Intangible assets	1.588	1.333
	Tangible fixed assets	1.571	1.386
	Inventories	-14	-5
	Other provisions	0	51
	Tax loss carryforwards	-422	-375
		2.723	2.390
	Net value is recognised in the balance sheet as follows:		
	Deferred tax asset	-462	-2.236
	Deferred tax liabilities	3.185	4.626
		2.723	2.390
	Development Deferred tax:		
0	Net value in balance sheet - primo year	2.390	1.775
0	Effect in P&L during the year	247	579
0	Effect on Equity during the year	86	36
0	Net value in balance sheet - ultimo year	2.723	2.390

# 16. Share capital

The share capital consists of 27,406m shares at EUR 0,13435

The shares have not been divided into classes.

There has not been any changes in share capital

# Notes

(1.000 EUR)

		Group		
	Due for payment within 1 year	Due for payment after 1 year	Amortized debt in total	Nominal debt in total
17. Long-term debt				
Mortgage debt	537	5.093	5.630	5.630
Bank loans	18.051	22.339	40.390	40.390
Long-term debt 31.12.2017	18.588	27.432	46.020	46.020
Long term debt 31.12.2016	10.868	45.364	56.232	56.232
Due for payment after 5 years:				
Mortgage debt		2.515		
Bank loans		0		
		2.515	C.r.o	
			Gro 2017	սբ 2016
18. Pledged assets and contingent liabilities Group:				
Mortgage deeds and letter of indemnity have been issued as securit institutions with a nominal amount of	y for credit		18.398	18.409
The actual liability on the balance sheet date amounts to			5.630	6.241
Carrying amount of mortgaged properties			15.872	15.450
Certain operating equipments have been financed by means of finar	ice leases.			
Total leasehold obligation until contracts expire			945	420
Leasehold liabilities			6.531	7.298

#### Group:

The Group has provided guarantees under which the guarantors assume joint and several liability for group companies net debt with bank and credit institution. The Groups total net debt in relation to this guarantee is booked at MEUR 90,3 at 31. December 2017.

The Group companies has provided receivables from sales of goods and services, MEUR 78,0, as security for debt to the Group's banks and credit institutions.

The Group companies are a party to litigation regarding alleged infringements of trademark and patent rights. Management believes that these legal proceedings will not lead to material losses for the company.

The Group has normal trade obligations on returned goods, and no significant losses are expected.

#### Parent company:

The company is jointly taxed with all Danish subsidiaries, with Habico Holding A/S as the administration company. The Company therefore held liable under the Corporation Tax Act rules for income taxes, and if any obligations to withhold tax on interest, royalties and dividends for the jointly taxed companies.

In addition, there are also security for the debt to banks and credit institutions, pledged unlisted shares in certain subsidiaries with a total book value per. 31. December 2017 of MEUR 77,9.

# Notes

(1.000 EUR)

Group	
2017	2016
-2.829	-29.369
-22.207	2.800
12.355	-3.897
-12.681	-30.466
39	3.086
-94.732	-96.847
-94.693	-93.761
	<b>2017</b> -2.829 -22.207 12.355 <b>-12.681</b> 39 -94.732

# 21. Related parties

Related parties with controlling interest in Habico A/S:

The parent company Habico Holding A/S, Central Business Registration No 27 34 71 34, Odense.

Other related parties Habico A/S has had transactions with in 2017:

The companies Board of Directors and Executive Board.

Fees etc. are separately disclosed in note 2, Staff costs.

All other transactions with related parties are eliminated in the overlying consolidated statements.

All transactions with related parties are carried out on arms length.

#### 22. Ownership

The company has registered the following shareholders to hold more than 5% of the voting share capital or of the nominal value of the share capital:

Habico Holding A/S, Energivej 15, 5260 Odense S.

#### 23. Consolidation

Name and registered office of the Parent preparing consolidated financial statement for the ultimative group: Habico Holding A/S, Energivej 15, 5260 Odense S, Denmark (Central Business Registration No 27 34 71 34).

Parent	company		Grou	up
2016	2017		2017	2016
		24. Fees to auditors appointed at the Company's general meeting		
		Fees are recognized under Other external expenses with:		
2	2	Audit	184	181
17	10	Other services	270	284
19	12		454	465

#### 25. Exchange rate risk and financial instruments

As part of the hedge of recognized and unrecognized transactions, the Group uses hedging instruments in the form of forward exchange contracts. Hedge of recognized transactions primarily comprise receivables and payables. The Group also uses interest rate swap to secure fixed interest on long term liabilities. The Group has secured MEUR 16,9 to a fixed rate of 2.1% with duration until medio 2019. As at 31.12.2017 unrealized net losses on derivative financial instruments for currency hedging and interest rate swap on Group level in total amounts TEUR 94. The amount is in the balance sheet included under other debt.

This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (large).

The accounting policies applied for these financial statements are consistent with those applied last year. The annual report is presented in EUR.

Income statement items are translated at the average rate for the year. Balance sheet items are translated at closing rate. The exchange rate adjustment from the average for the year, respectively, previous year's closing rate are posted directly to equity.

# **Recognition and measurement**

Assets are recognised in the balance sheet when it is probable as a result of a prior event, that future economic benefits will flow to the Group, and the value of the assets can be measured reliably.

Liabilities are recognised in the balance sheet when the Group has a legal or constructive obligation as a result of a prior event, and it is probable that future economic benefits will flow out of the Group, and the value of the liabilities can be measured reliably.

On initial recognition, assets and liabilities are measured at cost. Measurement subsequent to initial recognition is effected as described below for each financial statement item.

Anticipated risks and losses that arise before the time of presentation of the annual report and that confirm or invalidate affairs and conditions existing at the balance sheet date are considered at recognition and measurement.

Income is recognised in the income statement when earned, whereas costs are recognised by the amounts attributable to this financial year.

# The consolidated financial statements

The consolidated financial statements include Habico A/S (parent company) and companies (group enterprises) controlled by the parent, see the group overview page 8. The parent company is considered to have control when it directly or indirectly owns more than 50% of the voting rights or in other ways actually exercises controlling influence. Companies in which the Group directly or indirectly owns between 20% and 50% of the voting rights and exercises significant influence, but no controlling influence, are considered as associated companies. See the group over-view page 8.

# **Consolidation principles**

The consolidated financial statements are prepared on the basis of the financial statements for Habico A/S and it's subsidiaries. The consolidated financial statements are prepared by aggregation of uniform accounting items. On consolidation, elimination of intercompany revenue and expenses, and dividends as well as gains and losses on transactions between consolidated companies. The accounts used for consolidation are prepared in accordance with the groups accounting policies.

In the consolidated financial statement accounts of the subsidiaries are recognized 100%. Minority interests' proportionate share of net profit and net assets are presented as separate items in the income statement and balance sheet.

# **Business combinations**

Newly acquired or newly established enterprises are recognised in the consolidated financial statements from the time of acquiring or establishing such enterprises. Divested or wound-up enterprises are recognised in the consolidated income statement up to the time of their divestment or winding-up.

The purchase method is applied in the acquisition of new enterprises, under which identifiable assets and liabilities of these enterprises are measured at fair value at the acquisition date. On acquisition of enterprises, provisions are made for costs relating to decided and published restructurings in the acquired enterprise. Allowance is made for the tax effect of restatements.

Positive differences in amount (goodwill) between cost of the acquired share and fair value of the assets and liabilities acquired are recognised under intangible assets, and they are amortised systematically in the income statement based on an individual assessment of their useful lives. Negative differences in amount (negative goodwill), corresponding to an estimated adverse development in the relevant enterprises, are recognised in the balance sheet as a separate item under deferred income, and they are recognised in the income statement as such adverse development is realised.

# Profits or losses from divestment of equity investments

Profits or losses from divestment or winding-up of subsidiaries are calculated as the difference between selling price or settlement price and carrying amount of the net assets at the time of divestment or winding-up, inclusive of non-amortised goodwill and estimated expenses for divestment or winding-up.

# Foreign currency translation

On initial recognition, foreign currency transactions are translated applying the exchange rate at the transaction date. Receivables, payables and other monetary items denominated in foreign currencies that have not been settled at the balance sheet date are translated using the exchange rate at the balance sheet date. Exchange differences that arise between the rate at the transaction date and the rate in effect at the payment date or the rate at the balance sheet date are recognised in the income statement as financial income or financial expenses. Property, plant and equipment, intangible assets, inventories and other non-monetary assets that have been purchased in foreign currencies are translated using historical exchange rates.

On recognition of foreign subsidiaries which are independent units, all amounts are translated at the yearend rate. Differences in the exchange rate which arise when translating the foreign company's equity at the beginning of the year using the exchange rates at balance sheet date are recognised directly in equity.

# Derivatives

On initial recognition in the balance sheet, derivative financial instruments are measured at cost and subsequently at fair value. Derivative financial instruments are recognised under other receivables or other payables, respectively.

Changes in the fair value of derivative financial instruments classified as and complying with the requirements for hedging of the fair value of a recognised asset or a recognised liability are recorded in the income statement together with changes in the value of the hedged asset or the hedged liability.

Changes in the fair value of derivative financial instruments classified as and complying with the requirements for hedging future transactions are classified directly on equity. When the hedged transactions are realised, the accumulated changes are recognised as part of cost of the relevant financial statement items.

For derivative financial instruments that do not qualify as hedging instruments, changes in fair market value are recognised currently in the income statement as financial income or financial expenses.

Changes in the fair value of derivative financial instruments applied for hedging net investments in independent foreign group enterprises or associates are classified directly as equity.

# **Income statement**

#### Revenue

Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the determined consideration.

# Other operating income

Other operating income comprises income of a secondary nature to the Group's primary activities.

# Cost of sales

Cost of sales includes the consumption of commodities and freight costs that are incurred to generate the calculated revenue.

#### Other operating external expenses

Other external expenses comprise expenses for distribution, sale, advertising, administration, premises, etc.

# Staff costs

Staff costs comprise wages and salaries, social security costs, pension contributions, etc. for the Company's staff.

#### Income from investments in Group entities

Income from investments in group enterprises comprises the pro rata share of the individual enterprises' profit/loss after full elimination of intra-group profits or losses.

#### Financial income and expenses

These items comprise interest income and interest expenses, realised as well as unrealised capital gains and losses on liabilities and transactions in foreign currencies.

#### Income taxes

Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit/loss for the year and recognised directly in equity by the portion attributable to entries directly in equity. The portion of the tax taken to the income statement, which relates to extraordinary profit/loss for the year, is allocated to this entry whereas the remaining portion is taken to the year's profit/loss from ordinary activities.

Current tax payable or receivable is recognised in the balance sheet, stated as tax calculated on this year's taxable income, adjusted for prepaid tax.

Deferred tax is recognised on all temporary differences between the carrying amount and taxbased value of assets and liabilities, for which the taxbased value of assets is calculated based on the planned use of each asset.

Deferred tax is measured based on the tax regulations and tax rates of the relevant countries that will be in effect according to law at the balance sheet date when the deferred tax is estimated to be triggered as current tax. Changes in deferred tax resulting from changed tax rates are recognised in the income statement.

Deferred tax assets, including the tax base of tax loss carryforwards, are recognised in the balance sheet at their estimated realisable values, either as a set-off against deferred tax liabilities or as net tax assets.

The Parent is jointly taxed with all Danish subsidiaries and parent companies. The current Danish income tax is allocated among the jointly taxed companies proportionally to their taxable income (full allocation with a refund concerning tax losses).

The jointly taxed companies are subject to the rules of section 11B of the Danish Companies Act governing interest deduction limitation. It has been agreed in the joint taxation that reduced interest deduction is recognised in the company in which the interest deduction has been reduced.

# **Balance sheet**

# Goodwill

Goodwill is amortised straight-line over its estimated useful life which is fixed on the basis of the experience gained by Management for each business area.

The maximum amortization period of goodwill is 40 years.

The determination of the lifetime is decided based on an evaulation of a combined company with Know How, skills and a efficient organization, which is expected to provide development of the business in a long time to come, and because the lifetime of the medicinal products normally are very long.

When goodwill is subject to impairment, goodwill is written down to the lower of recoverable amount and carrying amount.

# Files and application fees

Files and application fees are measured at cost less accumulated amortisation and impairment losses.

Files and application fees regarding a specific product in relation to which a potential future market can be demonstrated and where the intention is to market the product in question are recognised as intangible assets. Other costs relating to applications are recognised as cost in the income statement as incurred.

Files and application fees regarding generic products are amortised straight-line over their expected useful lives calculated from the date when the product to which the files and application fees relate is introduced to the market. The amortisation period is 5-12 years.

When files and applications are subject to impairment, files and application fees are written down to the lower of recoverable amount and carrying amount.

# **Development projects in progress**

Development costs comprises costs, staff costs and depreciations, directly associated to development activities.

Development projects, which are clearly defined and identifiable, and where the technical viability, ressources and a potential future market kan be established with the intention to produce,market or utilise the projects, are recognised in the balance sheet as intangible assets, if the cost are measured reliable, and there is a certain security, that the future profit will cover the production-, marketing- and aministrations costs as well as development costs. Additional development costs are recognised in the income statement, as the costs occurs.

Development projects, are measured at cost less accumulated amortisation and impairment.

When development projects are completed, the products are amortised straight-line over their expected useful lives calculated from the date when the product to which the development cost relate is introduced to the market. The amortisation period usually used is 5-10 years.

# Other intangible assets

Cost of development and implementation of major IT systems as well as other intangible assets is measured at cost with deduction of accumulated amortisation and impairment losses. The period of amortisation is usually 3-7 years.

When other intangible assets are subject to impairment, other intangible assets are written down to the lower of recoverable amount and carrying amount.

# Property, plant and equipment

Properties, leasehold improvements and operating equipment are measured at cost less accumulated depreciation and impairment losses. Land is not depreciated.

Cost comprises the acquisition price, costs directly attributable to the acquisition, and preparation costs of the asset until the time when it is ready to be put into operation. Interest expenses are not included in cost.

The basis of depreciation is cost less estimated residual value after the end of useful life. The residual value amounts to 40% of the acquisition price. Straight-line depreciation is made on the basis of the following estimated useful lives of the assets:

Property:	10-50 years
Leasehold improvements:	5-10 years
Operating equipment:	3-10 years

Estimated useful lives and residual values are reassessed annually.

When property, plant and equipment are subject to impariment, PPE are written down to the lower of recoverable amount and carrying amount.

Profits and losses from the sale of property, plant and equipment are calculated as the difference between selling price less selling costs and the carrying amount at the time of sale. Profit or loss is recognised in the income statement.

# Investments in group enterprises

Investments in group enterprises are recognised and measured under the equity method. This means that investments are measured at the pro rata share of the enterprises' equity plus or minus unamortised goodwill or negative goodwill on consolidation and plus or minus unrealised intra-group profits and losses.

# Habico A/S

# **Accounting policies**

The Parent's share of the enterprises' profits or losses after elimination of unrealised intra-group profits and losses and plus or minus amortisation of positive, or negative, goodwill on consolidation is recognised in the income statement.

Group enterprises with negative equity are measured at zero value, and any receivables from these enterprises are written down by the Parent's share of such negative equity if it is deemed irrecoverable. If the negative equity value exceeds the amount receivable, the remaining amount is recognised under provisions if the Parent has a legal or constructive obligation to cover the liabilities of the relevant enterprise.

Net revaluation of investments in group enterprises is taken to reserve for net revaluation under the equity method if the carrying amount exceeds cost.

The purchase method is applied in the acquisition of investments in group enterprises; see above description under consolidated financial statements.

# Inventories

Inventories are measured at the lower of cost using the FIFO method and net realisable value.

Cost of goods for resale, raw materials and consumables consists of purchase price plus landing costs. Cost of manufactured goods and work in progress consists of costs of raw materials, consumables and direct labour costs as well as indirect production costs.

Indirect production costs comprise indirect materials and labour costs, costs of maintenance of and depreciation and impairment losses on machinery, factory buildings and equipment applied for the manufacturing process as well as costs of factory administration and management. Finance costs are not included in cost.

The net realisable value of inventories is calculated as the estimated selling price less completion costs and costs incurred to execute sale.

#### Receivables

Receivables are measured at amortised cost, usually equalling nominal value less write-downs for bad receivables.

# Prepayments

Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.

# Cash

Cash comprises cash in hand and bank deposits.

# Bank debt

Bank debt comprises debt to banks.

# Dividend

The proposed dividends for the financial year are recognised as equity.

#### Mortgage debt

At the time of borrowing, mortgage debt is measured at cost which corresponds to the proceeds received less transaction costs incurred. The mortgage debt is subsequently measured at amortised cost. This means that the difference between the proceeds at the time of borrowing and the nominal amount of the loan is recognised in the income statement as a financial expense over the term of the loan applying the effective interest method.

# Other financial liabilities

Other financial liabilities are measured at amortized cost, usually equaling nominal value of the liability.

# **Operating lease commitments**

Lease payments on operating leases are recognised on an ongoing basis in the income statement over the term of the lease.

# **Cash flow statement**

The cash flow statement of the Group is presented using the indirect method and shows cash flows from operating, investing and financing activities as well as the Group's cash and cash equivalents at the beginning and the end of the financial year. No separate cash flow statement has been prepared for the Parent because it is included in the consolidated cash flow statement.

Cash flows from acquisition and divestment of enterprises are shown separately under cash flows from investing activities. Cash flows from acquired enterprises are recognised in the cash flow statement from the time of their acquisition, and cash flows from divested enterprises are recognised up to the time of sale.

Cash flows from operating activities are calculated as the operating profit/loss adjusted for non-cash operating items, working capital changes and income taxes paid.

Cash flows from investing activities comprise payments in connection with acquisition and divestment of enterprises, activities and fixed asset investments as well as acquisition, development, improvement and sale, etc of intangible assets and property, plant and equipment.

Cash flows from financing activities comprise changes in the size or composition of the Parent's share capital and related costs as well as the raising of loans, inception of finance leases, instalments on interestbearing debt, purchase of treasury shares, and payment of dividend.

Cash and cash equivalents comprise cash and short-term securities with an insignificant price risk less short-term bank debt.

# Segment information

Information should be provided for business segments. No information is given in respect of geo-graphical markets as the risk to which the markets are subject is found to be quite similar.

# **Financial highlights**

Financial highlights are calculated as follows:

Gross margin:	<u>Gross profit x 100</u> Revenue
Operating margin:	<u>Operating income x 100</u> Revenue
Equity ratio:	<u>Equity x 100</u> Total assets
Return on equity:	Profit for the year x 100 Average equity